Clinical trials: Ophthalmic Solutions
Blepharo Conjunctivitis
To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension
The objective of the study is to compare and describe efficacy and safety of Tobradex ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of Blepharoconjuctivitis through clinical parameters
- Trial name
- NCT03975374
- Testing
- Tobramycin/dexamethasone opthalmic solution, Tobradex Opthalmic Solution
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Sutphin Drugs
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Cataract Extraction
Effect on Wound Healing of Vigamox Versus Cravit
The purpose of this study was to compare the effects of Vigamox and Cravit on corneal wound healing after cataract surgery.
- Trial name
- NCT00840580
- Testing
- Moxifloxacin 0.5% ophthalmic solution (Vigamox), Levofloxacin 0.5% ophthalmic solution (Cravit)
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03868124
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Glaukos Corporation
Dry Eye
A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease
This is a Phase 2 clinical study designed to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution compared with placebo in participants with dry eye disease. The study will enroll adults with dry eye disease.
- Trial name
- NCT07625124
- Testing
- RCI001 Ophthalmic Solution
- Volunteers
- 200 people
- Sponsor
- Rudacure
Mydriasis
Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution
The objective of this study is to explore pharmacodynamic effects and safety of IMP 08P2002F0 for dilation of the pupil, a solution combining two mydriatic agents tropicamide and phenylephrine hydrochloride at the concentrations…
- Trial name
- SOLMYD-PD (NCT07075224)
- Testing
- IMP 08P2002F0, Mydriasert® insert
- Where
- 2 sites in Greece
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Unither Pharmaceuticals, France
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects
SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a…
- Trial name
- NCT04324359
- Testing
- SURF-201
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- Surface Ophthalmics, Inc.
Dry Eye
Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05467293
- Testing
- 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 257 people
- Sponsor
- Yuyu Pharma, Inc.
Keratoconjunctivitis Sicca
Study of Rebamipide Eye Drops to Treat Dry Eye
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
- Trial name
- NCT00201955
- Testing
- Rebamipide 1%, Rebamipide 2%
- Where
- 60 sites in United States
- Volunteers
- 762 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dry Eye
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
- Trial name
- NCT07179055
- Testing
- VSJ-110
- Where
- 5 sites in United States
- Volunteers
- 160 people
- Sponsor
- Vanda Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Next Generation Rocklatan
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT06441643
- Testing
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 426 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
- Trial name
- NCT00244543
- Testing
- R89674 (generic name not yet established)
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Dry Eye
Study of EBI-005 in Dry Eye Disease (DED)
This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye…
- Trial name
- EBI-005 (NCT02405039)
- Testing
- EBI-005
- Where
- 12 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eleven Biotherapeutics
Vision Disorders
Study of A New Contact Lens Cleaning and Disinfecting Solution
The objective of this study is to evaluate the safety and efficacy of a new investigational cleaning and disinfecting solution (Test) compared to Clear Care cleaning and disinfecting solution (Control) when used by contact lens…
- Trial name
- NCT01318577
- Testing
- Investigational Cleaning & Disinfecting Solution, Clear Care Solution
- Where
- United States
- Volunteers
- 444 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Systane® Ultra Preservative Free Lubricant Eye Drops
The purpose of this post-market clinical follow-up (PMCF) study is to assess the performance and safety of Systane Ultra Preservative-Free (PF) in subjects experiencing dry eye symptoms (Group 1) and contact lens (CL) wearers…
- Trial name
- NCT05902364
- Testing
- Systane Ultra PF lubricant eye drops
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Macular Degeneration
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4…
- Trial name
- DREAM (NCT02222207)
- Testing
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Ranibizumab
- Where
- 149 sites in United States, Australia and 16 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
- Trial name
- NCT04782271
- Testing
- SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular…
- Trial name
- NCT03284853
- Testing
- Netarsudil/Latanoprost 0.02%/0.005%, GANFORT®
- Where
- 68 sites in Austria, Belgium and 9 more
- Volunteers
- 436 people
- Sponsor
- Aerie Pharmaceuticals
Opthalomology/Dry Eye
A Post-market Study to Evaluate the Effects of Sodium Hyaluronate Based Eye Drops in Patients Affected by Dry Eye Disease
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and…
- Trial name
- M-DED-2020 (NCT05773963)
- Testing
- Irilens; Iridina; Afomill Lubricating Eye Drops
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Montefarmaco OTC SpA
Myopia, Hyperopia
Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
A new multi-purpose solution (MPS)was clinically evaluated against Opti-Free RepleniSH MPS at specific time points over the course of four days. The study was conducted with PureVision lenses.
- Conditions
- Myopia, Hyperopia, Astigmatism
- Trial name
- NCT01024855
- Testing
- RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Optics